12:00 AM
 | 
Oct 22, 2007
 |  BioCentury  |  Regulation

Follow the biology

The biological rationale for using phosphate binders early in chronic kidney disease is straightforward: disruption of phosphate homeostasis is an early manifestation of the disease, and buildup of serum phosphorus leads to deleterious effects in patients long before they start dialysis.

Indeed, the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend early screening and treatment for hyperphosphatemia.

The foundation defines CKD as "structural or functional abnormalities of the kidneys for >=3 months, as manifested by either kidney damage with or without decreased glomerular filtration rate (GFR), or a GFR <60 mL/min/1.73 m2 with or without kidney...

Read the full 471 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >